Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
The latest update on Accuray centers on a sharp reset in its fair value estimate, with the target reduced from US$3.88 to US$0.35. Analysts are reworking their models to reflect more cautious assumptions, and that shift is feeding directly into revised price targets and a recalibrated narrative around what is realistic for the stock. As you read on, you will see how these changing views are taking shape and what to watch to stay on top of the evolving story around Accuray.
What Wall Street Has Been Saying 🐂 Bullish Takeaways
Even with recent caution, some commentary around Accuray still points to long term optionality if management can improve execution on its existing product base and tighten costs.
The reset in fair value estimates leaves the stock closer to levels where any progress on operations, orders, or margins could have a more visible impact on how analysts view the balance between upside and risk.
🐻 Bearish Takeaways
Jefferies and BTIG both downgraded Accuray, signaling reduced conviction in the earlier investment case and a more conservative stance on the stock’s risk and reward balance.
The sharp cut in the fair value estimate, including at firms such as Jefferies, highlights analyst concern around execution and growth prospects and is contributing to lower price targets and a more cautious outlook on valuation.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
NasdaqGS:ARAY 1-Year Stock Price Chart
We’ve flagged 3 risks for Accuray. See which could impact your investment.
How This Changes the Fair Value For Accuray
The fair value target has been reduced from US$3.88 to US$0.35.
The revenue growth assumption has shifted from a 4.20% increase to a 0.71% decline.
The net profit margin expectation has been adjusted from 12.91% to 11.88%.
The future P/E multiple has moved from 11.28x to 1.40x.
The discount rate has changed from 11.35% to 12.46%.
Never Miss an Update: Follow The Narrative
Narratives connect Accuray’s business story to analyst forecasts and fair value estimates by updating as new data and news flow through. They help you see how product developments, partnerships, and risks are feeding into the current outlook.
Head over to the Simply Wall St Community and follow the Narrative on Accuray to stay up to date on:
How global demand for precision and adaptive radiotherapy and the Stellar platform influence system placements and recurring service revenue.
The role of clinical and academic collaborations, including the University of Wisconsin partnership, in supporting evidence generation, training, and long term utilization of Accuray systems.
Key risks such as slower capital equipment purchasing in regions like EIMEA and China, margin pressure from tariffs and mix, and execution challenges in converting backlog to installations.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ARAY.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com